Viatris Valuation Multiples

Viatris Overview

About Viatris

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Founded

2014

HQ

Employees

32.0K

Website

viatris.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $14B

EBITDA: $4B

EV

$30B

Valuation Multiples

Multiples.vc

Start free trial

Viatris Financials

Viatris reported last 12-month revenue of $14B and EBITDA of $4B.

In the same LTM period, Viatris generated $7B in gross profit, $4B in EBITDA, and $3B in net income.

Viatris P&L

In the most recent fiscal year, Viatris reported revenue of $14B and EBITDA of $4B.

Viatris expects next 12-month revenue of XXX and NTM EBITDA of XXX

Viatris Stock Performance

Viatris has current market cap of $17B, and enterprise value of $30B.

Viatris' stock price is $14.68.

Viatris Valuation Multiples

Viatris trades at 2.1x EV/Revenue multiple, and 7.2x EV/EBITDA.

Viatris Financial Valuation Multiples

As of April 19, 2026, Viatris has market cap of $17B and EV of $30B.

Equity research analysts estimate Viatris' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Viatris has a P/E ratio of 6.1x.

Viatris Margins & Growth Rates

Viatris' revenue in the last 12 month grew by 2%.

Viatris' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Viatris' rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Viatris' rule of X is 35% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Viatris Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Viatris M&A Activity

Viatris acquired XXX companies to date.

Last acquisition by Viatris was on XXXXXXXX, XXXXX. Viatris acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Viatris Investment Activity

Viatris invested in XXX companies to date.

Viatris made its latest investment on XXXXXXXX, XXXXX. Viatris invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).